Back to top
more

Abbott Laboratories (ABT)

(Real Time Quote from BATS)

$106.09 USD

106.09
2,159,663

+2.10 (2.02%)

Updated Jun 20, 2024 12:38 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 41% (148 out of 249)

Industry: Medical - Products

Better trading starts here.

Zacks News

The Zacks Analyst Blog Highlights: Alphabet, Morgan Stanley, Abbott, Waste Management, General Mills and Raytheon

The Zacks Analyst Blog Highlights: Alphabet, Morgan Stanley, Abbott, Waste Management, General Mills and Raytheon

    Abbott Labs (ABT) Down 2.3% Since Earnings Report: Can It Rebound?

    Abbott Labs (ABT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

      The Zacks Analyst Blog Highlights: General Dynamics, EOG Resources, Abbott, Northrop Grumman and Symantec

      The Zacks Analyst Blog Highlights: General Dynamics, EOG Resources, Abbott, Northrop Grumman and Symantec

        Abbott Lab Well Poised on Strong EPD, St. Jude Integration

        On May 17, we issued an updated research report on Abbott Laboratories (ABT).

          Company News for April 20, 2017

          Companies in the News are: LRCX,FB,RARE,ABT

            Sheraz Mian headshot

            Q1 Scorecard & Stock Research Reports for IBM, Abbott and others

            Today's Research Daily features new research reports on 16 major stocks, including IBM (IBM), Abbott (ABT) and Dow Chemical (DOW).

              Abbott (ABT) Tops Q1 Earnings on Strong EPD, Medical Device

              Abbott Laboratories (ABT) reported first-quarter 2017 adjusted earnings from continuing operations of 48 cents per share, up 17.1% year over year.

                Abbott Laboratories (ABT) Tops Q1 Earnings & Sales Estimates

                Currently, Abbott Labs has a Zacks Rank #3 (Hold), but that could definitely change following the company's first quarter 2017 earnings report which was just released.

                  Company News for April 18, 2017

                  Companies in the News are: MGI,LLY,ASH,ALR,ABT

                    Company News for April 17, 2017

                    Companies in the News are: ABT,UAL,GS,PIR

                      Abbott Laboratories Agrees to Acquire Alere at Lower Price

                      Abbott has agreed to pay $51 per common share to acquire Alere, a reduction from earlier deal of $56 per common share upon the completion of the transaction.

                        Will Abbott Lab (ABT) Surprise Estimates in Q1 Earnings?

                        Abbott Laboratories (ABT) is scheduled to report first-quarter 2017 results before the opening bell on Apr 19.

                          Abbott's St Jude Buyout to Boost Business, Risks Remain

                          On Mar 31, we updated our research report on medical device major, Abbott Laboratories (ABT).

                            Sweta Killa headshot

                            Trump, Biogen and Amgen Hammer Healthcare ETFs

                            After making a strong comeback in February, the U.S. healthcare sector again witnessed some pain in the last couple of sessions.

                              Abbott Laboratories' MitraClip Outcome Positive for DMR

                              Abbott Laboratories (ABT) recently presented one-year positive outcomes from the study of the MitraClip system in transcatheter mitral valve repair (TMVR) procedures in the U.S.

                                Abbott Labs (ABT) Up 10.8% Since Earnings Report: Can It Continue?

                                Abbott Labs (ABT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                                  Acadia Healthcare (ACHC) Tops Q4 Earnings, Gives 2017 View

                                  Acadia Healthcare Company Inc. (ACHC) reported fourth-quarter 2016 adjusted earnings of 59 cents per share, which surpassed the Zacks Consensus Estimate by 4 cents.

                                    Parth Panchal headshot

                                    Abbott Laboratories Gains Despite Unimpressive Q4 Revenue Results

                                    Abbott Laboratories (ABT) just released its fourth quarter fiscal 2016 earnings results, posting earnings of $0.65 per share and revenue of $5.33 billion.

                                      Abbott Labs (ABT) Tops Q4 Earnings Estimates, Sales In Line

                                      Abbott Laboratories (ABT) reported fourth-quarter 2016 earnings from continuing operations of 65 cents per share, a penny higher than the Zacks Consensus Estimate.

                                        Abbott Laboratories (ABT): Tops Q4 Earnings, Sales in Line

                                        Abbott Laboratories (ABT) earnings per share has beaten the Zacks Consensus Estimated while its revenues were almost in line with the mar.

                                          Tracey Ryniec headshot

                                          3 Stocks with Great Earnings Charts

                                          Looking for stocks that beat on earnings nearly every quarter?

                                            What's in Store for Abbott Labs (ABT) This Earnings Season?

                                            Abbott Laboratories (ABT) is scheduled to report fourth-quarter and full year 2016 results before the opening bell on Jan 25.

                                              IDEXX Laboratories (IDXX) Set to Join the S&P 500 Index

                                              IDEXX Laboratories, Inc. (IDXX) is scheduled to join the coveted S&P 500 benchmark, after the market closes on Jan 4.

                                                Abbott Labs to Close St. Jude Acquisition Later this Week

                                                Abbott Laboratories (ABT) announced to close the acquisition of St. Jude Medical, Inc., (STJ) on Jan 4, 2017.

                                                  AbbVie's Humira and Imbruvica Drive Performance in 2016

                                                  AbbVie Inc.'s (ABBV) share price is up 5.9% so far this year.